Several studies demonstrate that use of commonly prescribed medications is associated with improved survival in various malignancies. Methods of classifying medication use in many of these studies, however, do not account for intermittent or cumulative use. Moreover, there are limited data in kidney cancer. Therefore, we performed a population-based cohort study utilizing healthcare databases in Ontario, Canada. We identified patients aged 65 with an incident diagnosis of kidney cancer between 1997 and 2013 and examined use of nine putative anti-neoplastic medications using prescription claims. Cox proportional hazard models evaluated the association of medication exposure on cancer-specific and overall survival. We conducted three separate analyses: the effect of cumulative duration of exposure to the study medications on outcomes, the effect of current exposure (in a binary nature) and the effect of exposure at diagnosis. During the 16-year study period, we studied 9,124 patients. Increasing cumulative use of angiotensin-converting enzyme inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs) and selective serotonin reuptake inhibitors were associated with markedly improved cancer-specific survival; increasing use of NSAIDs was associated with markedly improved overall survival. These results were generally discordant with analyses evaluating the effect of current use and exposure at diagnosis. In conclusion, pharmacoepidemiology studies may be sensitive to the method of analysis; cumulative use analyses may be the most robust as it accounts for intermittent use and supports a dose-outcome relationship. Prospective studies are needed to confirm whether patients diagnosed with kidney cancer should be started on an angiotensin-converting enzyme inhibitor, NSAID or selective serotonin reuptake inhibitor to improve survival.
Introduction
The incidence of kidney cancer is increasing in most countries 1 and is thought to be related to the increasing use of diagnostic imaging, as well as the rise in obesity and hypertension which are known risk factors for kidney cancer. 2 Despite earlier detection, survival rates have only marginally improved. 3 Several medications have recently gained interest in the oncology community for their putative anti-neoplastic effects, including angiotensin-converting enzyme inhibitors (ACEis), 4, 5 angiotensin II receptor blockers (ARBs), 4, 5 acetylsalicylic acid (ASA), 6 non-steroidal anti-inflammatory drugs (NSAIDs), 7, 8 beta blockers, 9,10 calcium channel blockers (CCBs), 11 selective serotonin reuptake inhibitors (SSRIs), 12 ,13 statins 14 and proton pump inhibitors (PPIs). 15 Randomized controlled trials are currently underway evaluating some of these medications as a stand-alone, or in combination therapy in the adjuvant or neoadjuvant setting for various malignancies. 16, 17 These medications are relatively inexpensive and generally well tolerated, and are therefore ideal candidates for chemoprevention. However, concerns have been raised about the potential for bias in pharmacoepidemiology studies in chemoprevention, particularly related to the method of classifying medication exposure. 18 Indeed, the majority of studies evaluating chemoprevention have not accounted for intermittent or cumulative use, including existing studies in kidney cancer, [19] [20] [21] [22] [23] [24] [25] [26] the majority of which have been retrospective studies in patients undergoing surgery. Therefore, the objectives of our study were twofold: (a) to evaluate the association between use of commonly prescribed medications with potential anti-neoplastic effects and survival in patients with incident kidney cancer; and (b) to compare different methods of classifying exposure to better understand the biases that may arise from pharmacoepidemiology studies.
Methods

Setting
We conducted a population-based retrospective cohort study of Ontarians aged 65 or older newly diagnosed with kidney cancer of any histology. Our study was approved by the Research Ethics Board of Sunnybrook Health Sciences Centre, Toronto, Ontario.
Data sources
We used the Ontario Cancer Registry (OCR) to identify patients with incident kidney cancer (ICD-9: 189.0; ICD-10: C64). We identified medication use through prescription claims of the Ontario Drug Benefit Database, which contains comprehensive records of prescription drugs dispensed to all Ontario residents aged 65 or older. We obtained hospitalization data from the Canadian Institute for Health Information Discharge Abstract Database, which contains detailed clinical information regarding all hospital admissions in Ontario. We used the Ontario Health Insurance Plan database to identify claims for physician services, and obtained basic demographic data and date of death from the Registered Persons Database, a registry of all Ontario residents eligible for health insurance. These databases were linked in an anonymous fashion using encoded health card numbers. Details regarding all databases used and their validity have been provided elsewhere. 27 
Study participants
We accrued patients from April 1st, 1997 until December 31st, 2013, following them until December 31st, 2011 (for cancer-specific mortality) and December 31st, 2014 (for allcause mortality). These dates were based on the most recent update of the database used for each outcome. All subjects had universal access to physician services, hospital care and prescription drug coverage. We deemed study subjects to have localized disease at presentation if they underwent surgery, radiofrequency ablation or cryotherapy as the first treatment following diagnosis of kidney cancer. Other subjects were deemed to have advanced disease if they received immune-or targeted therapy, or no intervention as their first treatment following diagnosis of kidney cancer. This classification is consistent with other studies conducted in Ontario. [27] [28] [29] Patients were excluded if they had a diagnosis of any malignancy (excluding non-melanoma skin cancers) prior to their kidney cancer diagnosis. This was done to exclude patients who may have worse outcomes due to their preexisting malignancy, rather than being an effect of kidney cancer or of putative anti-neoplastic medications. We also excluded patients whose histology indicated a primary malignancy other than kidney cancer.
Exposure assessment
We quantified medication exposure from the diagnosis of kidney cancer to the end of follow-up using prescription dates and the number of days supplied in each, as done previously. 30 This allowed for the calculation of the duration of cumulative exposure for each day of follow-up, as well as accounting for periods of intermittent use.
Outcome assessment
The primary outcome was cancer-specific survival and the secondary outcome was overall survival. For each outcome, patients were followed from date of diagnosis until their date of last contact with health services, death or the end of the study period, whichever occurred first.
Statistical methods
We conducted time-to-event analyses using multivariable Cox proportional hazard regression to estimate the effect of drug exposure on the risk of the primary and secondary outcomes.
What's new?
Certain common non-cancer drugs boost the odds of beating cancer. These authors examined the effect on survival of various drugs taken by kidney cancer patients. They tallied prescription claims from healthcare databases to compare cumulative use of nine different medications with cancer-specific and overall survival rate. By studying cumulative use, rather than current use, the authors were better able to consider the effects of taking these medications intermittently over time. Using data from more than 9,000 patients over a 16-year period, they showed that higher cumulative use of NSAIDs, ACE inhibitors and SSRIs correlated with better cancer-specific survival.
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For cancer-specific survival, we estimated the cause-specific hazard as we were interested in understanding the potential etiology of kidney cancer survival related to medication use. 31 Covariates in the model were selected a priori and included age at kidney cancer diagnosis, sex, comorbidity (defined by the Johns Hopkins ACG score from claims in the 5 years prior to cancer diagnosis 32 ), year of kidney cancer diagnosis (to account for temporal changes in exposures and outcomes), disease stage (localized vs. advanced), socioeconomic status, rurality and exposure to each medication after kidney cancer diagnosis.
We evaluated the association between medication exposure and outcomes in three ways. First, we examined cumulative medication use as a continuous time-dependent covariate. Second, we studied medication use as a binary time-dependent covariate denoting whether or not the subject was currently receiving the medication of interest (current use analysis). In this method, a patient could switch multiple times from an exposed to unexposed status, depending on the date and duration of their prescription. The first two models account for intermittent use; however, they evaluate different hypotheses. The cumulative use analysis evaluates whether increasing past use is associated with survival. In contrast, the current use analysis examines whether current or active use of a medication, as a binary variable, is associated with survival. Finally, while comprehensive prescription data allows us to perform the first two analyses, such analyses are often not feasible in institutional data. Therefore, our third method of analysis, used by many observational studies in pharmacoepidemiology, considered use vs. non-use at the time of diagnosis and was performed to evaluate whether results were consistent with methods accounting for intermittent use. For the analysis of cumulative use, we used the multivariable fractional polynomial algorithm to determine the functional form that best described the relationship between cumulative duration of exposure to each medication and the hazard of mortality. Since each day of incremental use is clinically insignificant, hazard ratios (HR) in this analysis are presented in increments per 6 months of use. The midpoint of each increment was compared to no use (0 month) to estimate the corresponding hazard ratio. In all analyses, all medications were modeled simultaneously to control for concomitant use.
All statistical analyses were performed using SAS (version 9.3; SAS Institute, Cary, NC) and used a two-sided p-value of 0.05 as the threshold for statistical significance.
Sensitivity analyses
To ensure that the results from the cumulative use analyses were robust, several sensitivity analyses were planned a priori:
(1) to minimize healthy user bias, whereby those who are more compliant with prescribed medications are those who are more likely to seek health care services, estimates were adjusted for the number of colonoscopies, fecal-occult blood tests and oculo-visual assessments in the first 5 years following kidney cancer diagnosis, adjusted for duration of follow-up; (2) to minimize confounding by indication, estimates were adjusted for comorbid conditions prior to kidney cancer diagnosis including history of hypertension, congestive heart failure, myocardial infarction, end stage renal disease and stroke and (3) to evaluate the impact of medication exposure prior to kidney cancer diagnosis, estimates were adjusted for cumulative exposure of medications from age 65 to kidney cancer diagnosis.
Results
Cohort characteristics
Over the 16-year study period, we identified 9,518 patients aged 65 or older with incident kidney cancer. Of these, 9,124 patients met the inclusion criteria ( Fig. 1 ). Their characteristics are described in Table 1 . During follow-up, 5,022 patients died, including 2,106 who died from kidney cancer. Medication use following kidney cancer diagnosis is shown in Table 2 .
Kidney cancer-specific survival
After applying the multivariable fractional polynomial algorithm, all medications were included in the final model evaluating cancer-specific survival (Table 3) . Cumulative use of ACEis, beta-blockers and ASA had a linear relationship with the log-hazard of the outcome, while non-identity transformations were required for the best functional form for the remaining medications (data supplement 1). Compared to no use, the first 6 months of exposure to ARBs and statins were associated with a slight increased risk of cancer-specific mortality. Conversely, the same duration of exposure to NSAIDs and SSRIs were associated with significantly improved cancer-specific survival. Compared to no use, exposure of 36-42 months of ACEis (HR 0.84, 95%CI 0.72-0.98), NSAIDs (HR 0.52, 95%CI 0.33-0.82) and SSRIs (HR 0.38, 95%CI 0.24-0.62) were associated with markedly reduced risk of cancer-specific mortality, while ARBs, statins and PPIs were associated with a modest reduced risk of cancer-specific mortality. In the current use analyses, ASA and NSAIDs were associated with significantly worse cancer-specific survival, while current use of ARBs, CCBs and statins were associated with improved cancer-specific survival (Table 3) .
In evaluating the association between use at the time of diagnosis and cancer-specific survival, only ARBs and CCBs were associated with significantly improved survival ( Table 3 ).
All-cause mortality
After applying the multivariable fractional polynomial algorithm, ACEis, ASA and CCBs were excluded from the final model evaluating overall survival (Table 4) . For no medication did cumulative duration of use follow a linear relationship with the log-hazard of the outcome and transformations were required for all medications (data supplement 1). Compared to no use, only exposure to NSAIDs for the first 6 months conferred a significant survival advantage. The benefits of NSAIDs exposure increased over time, with a 30% (HR 0.70, 95%CI 0.58-0.83) improvement in overall survival after 36-42 months of use. Compared to no use, exposure of 36-42 months of ARBs, statins or PPIs were associated with a modest improvement in overall survival, while betablockers were associated with modestly reduced overall survival.
In the current use analyses, ARBs, beta-blockers, NSAIDs and statins were associated with significantly improved overall survival (Table 4) .
Finally, use of beta-blockers, NSAIDs and SSRIs at the time of diagnosis was associated with significantly worse overall survival (Table 4) .
Sensitivity analyses
The associations between cumulative use of medications and survival outcomes were consistent in all sensitivity analyses, particularly the protective association of ACEis, NSAIDs and SSRIs with cancer-specific survival and NSAIDs with overall survival (data supplements 2-4).
Discussion
Our population-based cohort study evaluating nine putative anti-neoplastic medications in 9,124 patients with incident kidney cancer found that the associations between medication exposure and survival outcomes were dependent on the method of exposure classification. These findings have important implications for kidney cancer therapy and research in pharmacoepidemiology.
Comprehensive data on medication prescriptions is difficult to obtain outside of administrative data where the population is eligible for drug coverage. As such, the majority of studies evaluating chemoprevention in cancer have classified exposure in a dichotomous manner (use vs. non-use over a given period in time), [4] [5] [6] [7] [8] [9] [10] [11] 14, 15 including studies in kidney cancer. [19] [20] [21] [22] [23] [24] [25] This method of classifying exposure is prone to several biases, which limit the interpretation of the results from such studies. First, there is the potential for misclassification bias if patients classified as users subsequently discontinue therapy or vice-versa. This is particularly relevant when considering putative anti-neoplastic medications in the prospective setting. For example, a recent study evaluated the use statins in patients with kidney cancer and defined medication exposure as use at the time of surgery. 22 Their study found that statin use was associated with significantly improved disease-free survival and overall survival, and the authors suggested that statins be evaluated prospectively in kidney cancer. However, it is unknown how many patients continued statins after surgery; if many discontinued, the survival benefit observed in their study in the "user" group may reflect other explanations. Second, though not applicable in our method of classifying use vs. non-use at diagnosis, there is the potential for immortal-time bias if patients who begin medication after a certain amount of survival time are considered as users. 18 Indeed, a recent systematic review and meta-analysis evaluating beta-blockers and cancer survival found that when including all studies, beta-blocker use was associated with significantly improved overall and cancerspecific survival. 33 However, when excluding studies at high or unclear risk of immortal-time bias, the association between beta-blocker use was extinguished for overall survival, and approached the null for cancer-specific survival. Finally, there is the potential for selection bias with the simple comparison of users vs. non-users as these groups may differ with regard to their prognosis at baseline.
Cumulative use and current use analyses, however, mitigate these biases as they account for intermittent use. Indeed, it has been previously shown that analyses taking into account intermittent use do not correspond with results from analyses utilizing a dichotomous method of classifying exposure. 21, 34, 35 Furthermore, selection bias is offset as the same patient can contribute survival time to different exposure levels in the cumulative use analysis and to both the exposed and unexposed group in the current use analysis, depending on the dates and durations of prescription. Finally, the results from these analyses are more applicable to the clinical setting as only post-diagnostic use was evaluated, lending support for initiating a putative anti-neoplastic agent in patients with incident kidney cancer, rather than relying on prior exposure history.
Our results from the current and cumulative use analyses did not consistently suggest an association in the same direction. For example, NSAIDs were associated with a significantly increased risk of cancer-specific mortality in the current use analysis while the cumulative use analyses suggested that increasing use of NSAIDs conferred a survival advantage. This situation can arise if patients die while taking an NSAID, regardless of duration of exposure, while those with longer exposure have longer survival (data supplement 5). Conversely, statins demonstrated a markedly protective association on cancer-specific survival in the current use analysis, but a limited association in the cumulative use analysis. This situation can arise from a methodological perspective if patients with varying durations of statin exposure Cancer Epidemiology For cumulative use analyses, the hazard ratio was obtained by comparing the midpoint of each increment to no use (0 month). Adjusted for age, sex, comorbidity score, disease stage, socioeconomic status, rurality and year of diagnosis.
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1.00 (1.00-1.00)
1.00 (1.00-1.00) For cumulative use analyses, the hazard ratio was obtained by comparing the midpoint of each increment to no use (0 month). Adjusted for age, sex, comorbidity score, disease stage, socioeconomic status, rurality and year of diagnosis.
tended to die after the end of their prescription (data supplement 5). From a biological perspective, this may occur if the putative anti-neoplastic effects may be limited to the duration that the medication is present in the circulation. This is consistent with the observed effects upon the discontinuation of tyrosine kinase inhibitors, such as sunitinib (half-life 40-60 hr) or pazopanib (half-life 31 hr), which results in accelerated tumor growth and tumor flare in kidney cancer patients. 36 More recently, a sub-analysis of a phase 3 randomized trial comparing pazopanib with placebo as adjuvant treatment for patients undergoing nephrectomy for locally advanced kidney cancer found that a higher pazopanib trough level was associated improved disease-free survival; 37 evaluating the relationship between trough levels of putative anti-neoplastic medications and survival may further our understanding of the appropriate duration and dosage of chemoprevention therapy.
While the current use analysis is more robust than a simple comparison of users vs. non-users, we propose that cumulative use analyses are the most appropriate as they allow for an evaluation of a dose-response relationship, supporting causality for chemoprevention. 38 Our results suggest that ACEis and SSRIs are potential candidates to improve cancer-specific survival, while NSAIDs may improve both cancer-specific and overall survival. These results were consistent in several sensitivity analyses. 42, 43 Indeed, kidney cancer has been described as a metabolic disease, involving dysregulation of various metabolic pathways. 44 Further study on the potential effect of putative anti-neoplastic medications on these pathways may allow for identification of targeted therapy based on tumor subtype and for synergistic combination therapy. Given that health care is publicly administered in Ontario, our study has several strengths. First, selection bias is minimized compared to institutional cohorts. Second, the availability of comprehensive prescription data allows for more robust analyses evaluating medication exposure. Third, the majority of studies in cancer chemoprevention have evaluated a single medication or medication class. In contrast, we evaluated multiple medications simultaneously, allowing us to determine the independent association of each medication with survival outcomes. Furthermore, we performed several sensitivity analyses to ensure the robustness of the results. Finally, the results of our study are generalizable to patients aged 65 or older with an incident diagnosis of kidney cancer. While randomized controlled trials provide the strongest level of evidence, patients included in randomized controlled trials tend to be younger and healthier and may not be representative of all patients with kidney cancer.
Our study has also several limitations. First, various factors govern whether or not patients will be exposed to putative anti-neoplastic medications (such as physician preference) or experience all-cause or cancer-specific mortality (such as tumor characteristics) that were not available in our study. However, these do not represent true confounders because they are not associated with both exposure and outcome. As such, controlling for these factors will not improve the estimation of the exposure-outcome relationship; rather, it would reduce statistical precision. Furthermore, many studies have shown that tumor stage was not significantly different in users vs. non-users of some of the putative anti-neoplastic studies evaluated. 21, 22, 24, 26 Although we attempted to control for disease burden based on the intervention received after kidney cancer diagnosis, this method is prone to misclassification as a patient with localized disease may undergo observation for their cancer, and a patient with advanced disease may undergo a cytoreductive nephrectomy. The hazard ratio associated with advanced disease stage (5.4 for cancer-specific survival and 3.6 for overall survival), however, suggests against a strong effect of misclassification. Limited data on treatment details also precluded adjustment for dose reduction of tyrosine kinase inhibitors, which has been associated with prognosis in advanced kidney cancer. 45 Second, since the dates of prescription and the days supplied field were used as a surrogate for medication exposure, the actual exposure may not correspond to the estimated exposure if patients are noncompliant with their medication prescriptions. However, patients that consistently renew their prescriptions are likely compliant; indeed, both the cumulative and time-varying analyses account for the lapses between prescriptions. Third, we could not account for medication exposure prior to age 65 because this data is incomplete. However, it has previously been shown that exposure to putative anti-neoplastic medications prior to cancer diagnosis was not associated with survival outcomes. 30, 46 Fourth, secondary data with imperfect sensitivity and specificity were used for the study. However, several of the databases have been validated. 27 Fifth, multiple associations were evaluated, increasing the probability of a Type I error. However, even after controlling for the false discovery rate, 47 all significant associations in the original analysis remained significant. Finally, many NSAIDs are available over the counter and it is possible that some exposure was not captured due to this. However, considering that patients would not have to pay for medication had they obtained it by prescription, it is unlikely that over the counter exposure would bias the results to a strong degree. Furthermore, it has been demonstrated that using administrative data for NSAIDs exposure is a reasonable estimate of actual exposure, despite availability of these drugs over the counter. 48 Despite these limitations, this is the first study to simultaneously evaluate multiple putative anti-neoplastic medications in patients with kidney cancer and suggests that ACEis, NSAIDs and SSRIs may have a role in kidney cancer therapy.
In summary, our study evaluating the association of putative anti-neoplastic medications on survival outcomes in patients with kidney cancer found that the results were dependent on the method of classifying medication exposure. We propose that cumulative use analyses are the most robust and future studies in chemoprevention should utilize this method. The results from cumulative use analyses in our study suggest that angiotensin converting enzyme inhibitors, selective serotonin reuptake inhibitors and non-steroidal antiinflammatory drugs may have a role in improving survival outcomes in patients with kidney cancer.
